Product Pathways - Apoptosis
DR5 Antibody #3696
Reactivity Key: H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.
Specificity / Sensitivity
DR5 Antibody detects the precursor and mature forms of isoforms 1 and 2 of DR5. Cross reactivity was not detected with other family members.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding cysteine 248 of isoform 1 of human DR5. Antibodies were purified by protein A and peptide affinity chromatography.
Western blot analysis of extracts from HeLa cells either mock transfected or transfected with a DR5 cDNA, using DR5 Antibody.
The tumor necrosis factor receptor family, which includes TNF-RI, Fas, DR3, DR4, DR5, and DR6, plays an important role in the regulation of apoptosis in various physiological systems (1,2). The receptors are activated by a family of cytokines that include TNF, FasL, and TRAIL. They are characterized by a highly conserved extracellular region containing cysteine-rich repeats and a conserved intracellular region of about 80 amino acids termed the death domain (DD). The DD is important for transducing the death signal by recruiting other DD containing adaptor proteins (FADD, TRADD, RIP) to the death-inducing signaling complex (DISC), resulting in activation of caspases.
DR5 is a receptor for TNF-related apoptosis inducing ligand (TRAIL), which has been been shown to induce apoptosis in variety of cell types and has been targeted for cancer therapy (1-5). Structurally, DR5 contains an amino-terminal leader cleavage site followed by an extracellular region containing two cysteine-rich repeats, then a central transmembrane domain and a carboxy-terminal death domain. DR5 is expressed in a wide variety of tissues and is transcriptional target for p53 (6-8). It induces apoptosis through a FADD-dependent pathway. Deletion of DR5 leads to resistance in TRAIL-mediated apoptosis as well as an abrogated response to DNA-damaging stimuli (9).
- Nagata, S. (1997) Cell 88, 355-365.
- Thorburn, A. (2004) Cell. Signal. 16, 139-144.
- Wiley, S.R. et al. (1995) Immunity 3, 673-82.
- Walczak, H. et al. (1997) EMBO J. 16, 5386-97.
- Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
- MacFarlane, M. et al. (1997) J. Biol. Chem. 272, 25417-20.
- Wu, G.S. et al. (2000) Adv. Exp. Med. Biol. 465, 143-51.
- Wu, G.S. et al. (1997) Nat. Genet. 17, 141-3.
- Finnberg, N. et al. (2005) Mol. Cell Biol. 25, 2000-13.
- Duiker, E.W. et al. (2009) Clin Cancer Res 15, 2048-57. Applications: Western Blotting
- Lee, M.S. et al. (2010) Infect Immun 78, 3378-91. Applications: Western Blotting
- Rajeshkumar, N.V. et al. (2010) Mol Cancer Ther 9, 2582-92. Applications: Western Blotting
- Tian, X. et al. (2011) J Biol Chem 286, 29408-16. Applications: Western Blotting
- Huang, Y. et al. (2011) Endocr Relat Cancer 18, 13-26. Applications: Western Blotting
- Mazumdar, T. et al. (2011) Cancer Res 71, 1092-102. Applications: Western Blotting
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
- 3707 TNF-α Antibody
- 4273 FasL Antibody
- 2782 FADD Antibody (Human Specific)
- 3684 TRADD (7G8) Rabbit mAb
- 4926 RIP Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
For Research Use Only. Not For Use In Diagnostic Procedures.